These studies clearly indicate that blocking key recruitment chemokine receptors such as CCR2 and/or CCR5 is a promising therapeutic avenue to ameliorate common diabetic complications such as nephropathy and retinopathy. The gene discussed is CCR2; the disease is retinal disorder.